<DOC>
	<DOCNO>NCT02768649</DOCNO>
	<brief_summary>The purpose study assess safety tolerability injection RBP-7000 subject stable schizophrenia</brief_summary>
	<brief_title>Single Ascending Dose Study RBP-7000</brief_title>
	<detailed_description>This open-label , single-center , Phase 1 , single ascend dose study , design evaluate safety , tolerability , pharmacokinetic ( PK ) profile single SC injection low , medium high dose RBP-7000 subject clinically stable schizophrenia take risperidone . The design sequential cohort treatment initiate 3 cohort safety tolerability lower dose confirm . Eligible subject receive single oral test dose 0.25mg risperidone medical supervision . Subjects continue eligible admit residential unit approximately 14 day , receive single dose RBP-7000 . Subjects discharge Day 15 return clinical site weekly approximately 10 week .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Subjects confirm diagnosis paranoid , residual , undifferentiated schizophrenia document letter subject 's psychiatrist primary care provider . Clinically stable subject ( subject PI establish medical record history subject least 1 reliable informant , subject clinically stable least 60 day without hospitalization ) . Subjects body mass index ( BMI ) 18 33 kg/m2 weight least 49.9 kg . Subjects give write informed consent . Subjects take risperidone product within last 60 day prior study screen . Subjects history cancer ( exclude resect basal cell squamous cell carcinoma skin ) unless disease free ≥ 5 year . Subjects another active medical condition organ disease could either compromise subject safety interfere safety and/or outcome evaluation study drug . This include , limit follow abnormality : total bilirubin &gt; 2.5 mg/dL ( 51 μmol/L ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3 × upper limit normal ( ULN ) clinically significant serum creatinine &gt; 2 x ULN , international normalize ratio ( INR ) ≥ 2.0 . Other exclude medical condition include , limited : history heart attack , brain injury , low blood pressure , clinically significant irregular heartbeat interpret PI . Subjects know acquire immune deficiency syndrome human immunodeficiency virus ( HIV ) positive . Subjects evidence history significant hepatic disorder , include acute chronic hepatitis B acute hepatitis C. Subjects hepatitis C antibody liver function ≤ 1.5 time ULN could include study . Subjects know diagnosis type 1 2 diabetes subject clinically significant abnormal hemoglobin A1c ( HbA1c ) screen interpret PI . Subjects clinically significant comorbidities could affect nearterm survival . Subjects treat investigational drug within last 30 day prior study screen . Subjects significant traumatic injury , major surgery , open biopsy within last 4 week prior study screen . Subjects receive opioid opioidcontaining analgesic within last 30 day prior study screen . Subjects consume &gt; 1 alcoholic drink per day within last 30 day prior study screen ( define 1 oz . 80 proof spirit , 12 oz . beer , 4 oz . wine ) . Subjects prior allergic reaction , sensitivity , know contraindication component RBP7000 ( i.e. , risperidone , poly [ DLlactidecoglycolide ] , Nmethylpyrrolidone ) . Subjects concurrent uncontrolled illness may interfere ability participate study . Women positive pregnancy test screening . Women childbearing potential , pregnant lactating , seek pregnancy , fail take adequate contraceptive precaution ( e.g. , oral injectable contraceptive , approve hormonal implant topical patch , intrauterine device ) . Should female subject become sexually active , must agree use doublebarrier method barrier plus spermicide . A woman childbearing potential define female less 2 year postmenopausal undergone hysterectomy surgical sterilization , e.g. , bilateral tubal ligation bilateral ovariectomy ( oophorectomy ) . Females postmenopausal confirm follicle stimulate hormone ( FSH ) test initial screening . Subjects positive urine drug screen opioids , cocaine , amphetamine , methadone , marijuana , barbiturate , benzodiazepine , methamphetamine , phencyclidine , tricyclic antidepressant unless positive screen determine secondary allowable concomitant medication . Subjects epilepsy seizure disorder , Parkinson 's disease , dementia . Subjects take bupropion , chlorpheniramine , cimetidine , clomipramine , doxepin , quinidine within last 30 day prior study screen . Subjects take clozapine , phenothiazine , aripiprazole , haloperidol within last 30 day prior study screen . Subjects take serotonin reuptake inhibitor ( e.g. , fluoxetine , paroxetine ) within last 30 day prior study screen . Subjects take medication , addition list , may expect significantly interfere metabolism excretion risperidone and/or 9hydroxyrisperidone may associate significant drug interaction risperidone , may pose significant risk subject ' participation study . Subjects previously inject RBP7000 study . Subjects unable , opinion PI , comply fully study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>